| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000029582 |
| Receipt No. | R000033794 |
| Official scientific title of the study | The verification study of improvements in psychological stress: a randomized double-blind, parallel-group, placebo-controlled trial |
| Date of disclosure of the study information | 2017/10/16 |
| Last modified on | 2018/07/19 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | The verification study of improvements in psychological stress: a randomized double-blind, parallel-group, placebo-controlled trial | |
| Title of the study (Brief title) | The verification study of improvements in psychological stress | |
| Region |
|
|
| Condition | |||
| Condition | Healthy Japanese adults | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To verify the improvement of psychological stress with intake of the test food |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Autonomic function
* Assess at screening and examination before consuming and at 4 and 8 weeks after consuming. Perform the test before and after psychological stress load. |
| Key secondary outcomes | 1. Salivary amylase activity
2. Salivary cortisol activity 3. Pepsinogen I (PGI) 4. Pepsinogen II (PGII) 5. PGI/PGII 6. Profile of Mood States 2nd Edition (POMS2) Japanese version 7. Izumo Scale 8. Original questionnaires 8a. Visual Analogue Scale (VAS) 8b. Likert scale *1-6,8a Assess at screening and examination before consuming and at 4 and 8 weeks after consuming. Perform these assessments before and after psychological stress load. *7,8b Assess at screening and examination before consuming and at 4 and 8 weeks after consuming. Perform the assessment before psychological stress load. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Duration: 8 weeks
Test material: Active capsule Dose: Take 3 capsules per day Administration: Take a capsule after breakfast, lunch, and dinner. * If you cannot eat either breakfast or lunch, take 2 capsules of the test food at once after next meal within the day. If you cannot eat dinner, take the test food in the evening. * If you forget to take the capsule, take it as soon as you remember within the day. |
|
| Interventions/Control_2 | Duration: 8 weeks
Test material: Placebo capsule Dose: Take 3 capsules per day Administration: Take a capsule after breakfast, lunch, and dinner. * If you cannot eat breakfast or lunch, take 2 capsules of the test food at once after next meal within the day. If you cannot eat dinner, take the test food in the evening. * If you forget to take the capsule, take it as soon as you remember within the day. |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Healthy Japanese adults
2. Subjects experiencing stress in daily 3. Subjects whose the result of the Helicobacter pylori antibody test is negative at screening and examination before ingestion and are judged as eligible to participate in the study by the principal investigator 4. Among the subjects who met 3rd inclusion criteria, subjects whose LF/HF ratio at autonomic function test is relatively high |
|||
| Key exclusion criteria | 1. At least one previous medical history or under the treatment of malignant tumor, heart failure or myocardial infarction
2. Currently under the treatment for either cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or other chronic diseases 3. Subjects who use or take "Foods for Specified Health Uses" and "Foods with Functional Claims" in daily 4. Currently taking medicines (include herbal medicines) and supplements 5. Subjects who are allergic to medicines and/or the test food related products 6. Subjects who are pregnant, breast-feeding, and plan to become pregnant 7. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial 8. Subjects who are judged as ineligible to participate in the study by the principal investigator 9. Subjects who have been diagnosed with Helicobacter pylori infection |
|||
| Target sample size | 40 | |||
| Research contact person | |
| Name of lead principal investigator | Kazuo YAMAMOTO |
| Organization | ORTHOMEDICO Inc. |
| Division name | CEO |
| Address | 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan. |
| TEL | 03-3818-0610 |
| kazu@orthomedico.jp | |
| Public contact | |
| Name of contact person | Naoko SUZUKI |
| Organization | ORTHOMEDICO Inc. |
| Division name | R&D Department |
| Address | 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan. |
| TEL | 03-3818-0610 |
| Homepage URL | |
| nao@orthomedico.jp | |
| Sponsor | |
| Institute | ORTHOMEDICO Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | MITSUBISHI-CHEMICAL FOODS CORPORATION |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Medical Corporation Seishinkai, Takara Clinic |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033794 |